$BEAM
Beam Therapeutics Inc. Stock $beam

$beam Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000095017022008238 Filed on May 09, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$8.432M	$6.000K
YoY Change	140433.33%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$19.25M	$10.27M
YoY Change	87.41%	50.81%
% of Gross Profit
Research & Development	$65.41M	$190.1M
YoY Change	-65.59%	782.2%
% of Gross Profit
Depreciation & Amortization	$3.312M	$1.398M
YoY Change	136.91%	27.09%
% of Gross Profit
Operating Expenses	$84.66M	$200.4M
YoY Change	-57.75%	606.53%
Operating Profit	-$76.23M	-$200.4M
YoY Change	-61.96%	606.66%
Interest Expense	$6.559M	-$880.0K
YoY Change	-845.34%	-58.1%
% of Operating Profit
Other Income/Expense, Net	$7.011M	-$1.187M
YoY Change	-690.65%
Pretax Income	-$69.21M	-$201.6M
YoY Change	-65.66%	561.72%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$69.21M	-$201.6M
YoY Change	-65.66%	561.76%
Net Earnings / Revenue	-820.85%	-3359333.33%
Basic Earnings Per Share	-$1.01	-$3.35
Diluted Earnings Per Share	-$1.01	-$3.35
COMMON SHARES
Basic Shares Outstanding	68.70M	60.21M
Diluted Shares Outstanding	68.70M	60.21M

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.223B	$503.5M
YoY Change	142.82%	98.7%
Cash & Equivalents	$296.8M	$97.24M
Short-Term Investments	$925.8M	$406.2M
Other Short-Term Assets	$16.88M	$11.10M
YoY Change	52.11%	79.03%
Inventory
Prepaid Expenses
Receivables	$0.00
Other Receivables	$0.00
Total Short-Term Assets	$1.239B	$514.6M
YoY Change	140.87%	98.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$94.29M	$51.99M
YoY Change	81.34%	10.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.341M	$5.033M
YoY Change	-73.36%	-68.74%
Total Long-Term Assets	$213.9M	$178.7M
YoY Change	19.73%	183.59%
TOTAL ASSETS
Total Short-Term Assets	$1.239B	$514.6M
Total Long-Term Assets	$213.9M	$178.7M
Total Assets	$1.453B	$693.2M
YoY Change	109.65%	114.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.266M	$7.983M
YoY Change	-21.51%	30.87%
Accrued Expenses	$66.55M	$18.90M
YoY Change	252.1%	43.18%
Deferred Revenue	$115.0M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.337M	$2.100M
YoY Change	11.29%	23.53%
Total Short-Term Liabilities	$218.8M	$102.1M
YoY Change	114.33%	225.11%
LONG-TERM LIABILITIES
Long-Term Debt	$2.404M	$4.700M
YoY Change	-48.85%	-11.32%
Other Long-Term Liabilities	$11.09M	$1.342M
YoY Change	726.38%	-94.52%
Total Long-Term Liabilities	$11.09M	$1.342M
YoY Change	726.38%	-95.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$218.8M	$102.1M
Total Long-Term Liabilities	$11.09M	$1.342M
Total Liabilities	$624.3M	$270.8M
YoY Change	130.54%	342.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$837.5M	-$599.2M
YoY Change	39.77%
Common Stock	$698.0K	$617.0K
YoY Change	13.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$829.1M	$422.4M
YoY Change
Total Liabilities & Shareholders Equity	$1.453B	$693.2M
YoY Change	109.65%	114.89%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$69.21M	-$201.6M
YoY Change	-65.66%	561.76%
Depreciation, Depletion And Amortization	$3.312M	$1.398M
YoY Change	136.91%	27.09%
Cash From Operating Activities	$218.5M	-$38.58M
YoY Change	-666.36%	40.83%
INVESTING ACTIVITIES
Capital Expenditures	$7.259M	$11.48M
YoY Change	-36.76%	276.82%
Acquisitions		-$620.0K
YoY Change
Other Investing Activities	-$530.1M	-$268.1M
YoY Change	97.68%	263.59%
Cash From Investing Activities	-$537.3M	-$279.6M
YoY Change	92.16%	264.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$54.00M	$260.0M
YoY Change	-79.23%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	55.68M	253.3M
YoY Change	-78.02%	31.22%
NET CHANGE
Cash From Operating Activities	218.5M	-38.58M
Cash From Investing Activities	-537.3M	-279.6M
Cash From Financing Activities	55.68M	253.3M
Net Change In Cash	-263.2M	-64.93M
YoY Change	305.32%	-173.1%
FREE CASH FLOW
Cash From Operating Activities	$218.5M	-$38.58M
Capital Expenditures	$7.259M	$11.48M
Free Cash Flow	$211.2M	-$50.06M
YoY Change	-521.99%	64.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
CY2022Q1	dei	City Area Code CityAreaCode	857
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	327-8775
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001745999
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2021Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#LicenseMember
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-39208
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Beam Therapeutics Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-5238376
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	238 Main Street
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	BEAM
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70266761
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296821000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	559994000
CY2022Q1	beam	Available For Sale Debt Securities And Equity Securities Fv Ni Current AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent	925779000
CY2021Q4	beam	Available For Sale Debt Securities And Equity Securities Fv Ni Current AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiCurrent	405653000
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	136034000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	134810000
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2404000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3007000
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	30915000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	31367000
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	225093000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	beam	Collaboration Receivable Current CollaborationReceivableCurrent	300000000
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16884000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7360000
CY2022Q1	us-gaap	Assets Current AssetsCurrent	1239484000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1273007000
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94288000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84258000
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	12746000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	12746000
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	105543000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	102718000
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1341000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1724000
CY2022Q1	us-gaap	Assets Assets	1453402000
CY2021Q4	us-gaap	Assets Assets	1474453000
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6266000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7474000
CY2022Q1	beam	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	24062000
CY2021Q4	beam	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	28921000
CY2022Q1	beam	Accrued Sub License Fees Current AccruedSubLicenseFeesCurrent	33125000
CY2021Q4	beam	Accrued Sub License Fees Current AccruedSubLicenseFeesCurrent	38743000
CY2022Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	28600000
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	42200000
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	115049000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	86270000
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9359000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7540000
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2337000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2287000
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	218798000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	213435000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	262303000
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	11090000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2793000
CY2022Q1	us-gaap	Liabilities Liabilities	624334000
CY2021Q4	us-gaap	Liabilities Liabilities	647715000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2021Q1	beam	Change In Fair Value Of Contingent Consideration Liabilities ChangeInFairValueOfContingentConsiderationLiabilities	305000
CY2022Q1	beam	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	644000
CY2021Q1	beam	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-21000
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7011000
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.35
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.35
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68703864
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69785836
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	68581251
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69753023
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	68389425
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	698000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	684000
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1668567000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1594378000
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2709000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-50000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-837488000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-768274000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	829068000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	826738000
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1453402000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1474453000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8432000
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65410000
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	190106000
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19247000
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10273000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	84657000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	200379000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-76225000
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-200373000
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	13600000
CY2021Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1900000
CY2022Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-7685000
CY2021Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	1039000
CY2022Q1	beam	Change In Fair Value Of Contingent Consideration Liabilities ChangeInFairValueOfContingentConsiderationLiabilities	-452000
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1187000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-69214000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-201560000
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2659000
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-15000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71873000
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-201575000
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2021Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-63000
CY2021Q1	beam	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	1900000
CY2022Q1	beam	Change In Fair Value Of Contingent Consideration Liabilities ChangeInFairValueOfContingentConsiderationLiabilities	-452000
CY2021Q1	beam	Change In Fair Value Of Contingent Consideration Liabilities ChangeInFairValueOfContingentConsiderationLiabilities	305000
CY2022Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-7685000
CY2021Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	1039000
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3000
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68703864
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60210120
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60210120
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	245561000
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	252005000
CY2021Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	120032000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4648000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1758000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-201560000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	422429000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	826738000
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1412000
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53936000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18035000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	820000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2659000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-69214000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	829068000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-69214000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-201560000
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3312000
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1398000
CY2022Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	390000
CY2021Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-15000
CY2021Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	154953000
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	18035000
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4648000
CY2022Q1	beam	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	1997000
CY2021Q1	beam	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	2359000
CY2022Q1	beam	Change In Fair Value Of Derivative Liabilities ChangeInFairValueOfDerivativeLiabilities	-13600000
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9185000
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2365000
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	185000
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1252000
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-666000
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-16533000
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4458000
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1780000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	309567000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	112081000
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	113000
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	159000
CY2021Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	6111000
CY2022Q1	beam	Increase Decrease In Collaboration Receivable IncreaseDecreaseInCollaborationReceivable	-300000000
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8432000
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6000
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	8296000
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-51000
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	218490000
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38578000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7259000
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11478000
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	690390000
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	289218000
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	160310000
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	20450000
CY2021Q1	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	620000
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-537339000
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-279626000
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	54003000
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	260000000
CY2022Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1412000
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	6000
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	7955000
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	553000
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	529000
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	820000
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1758000
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55676000
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	253274000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-263173000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-64930000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	572740000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	177011000
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	15306000
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6671000
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4822000
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	23366000
CY2022Q1	beam	Equity Issuance Costs In Accounts Payable And Accrued Expenses EquityIssuanceCostsInAccountsPayableAndAccruedExpenses	67000
CY2021Q1	beam	Equity Issuance Costs In Accounts Payable And Accrued Expenses EquityIssuanceCostsInAccountsPayableAndAccruedExpenses	250000
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	36513000
CY2021Q1	beam	Fair Value Of Equity Instruments Issued In Connection With Asset Acquisition FairValueOfEquityInstrumentsIssuedInConnectionWithAssetAcquisition	120032000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-837500000
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19334000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16081000
CY2022Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1200000000
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, incremental borrowing rate used in the calculation of lease liabilities, research and development expenses, stock-based compensation, contingent consideration liabilities, success payments and certain judgements regarding revenue recognition. Actual results could differ from these estimates.</span></p>
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	94288000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	84258000
CY2022Q1	beam	Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis	928488000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	296821000
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97241000
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	12746000
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	14840000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	309567000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	112081000
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	113622000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	100339000
CY2022Q1	us-gaap	Depreciation Depreciation	3262000
CY2021Q1	us-gaap	Depreciation Depreciation	1398000
CY2022Q1	beam	Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes	2000
CY2022Q1	beam	Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Taxes AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes	2711000
CY2022Q1	beam	Available For Sale Debt Securities And Equity Securities Fv Ni AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi	925779000
CY2021Q4	beam	Available For Sale Debt Securities And Equity Securities Fv Ni Amortized Cost Basis AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAmortizedCostBasis	405703000
CY2021Q4	beam	Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Taxes AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTaxes	32000
CY2021Q4	beam	Available For Sale Debt Securities And Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Taxes AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTaxes	82000
CY2021Q4	beam	Available For Sale Debt Securities And Equity Securities Fv Ni AvailableForSaleDebtSecuritiesAndEquitySecuritiesFvNi	405653000
CY2022Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0
CY2021Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0
CY2022Q1	beam	Debt Securities Available For Sale Maturity Period DebtSecuritiesAvailableForSaleMaturityPeriod	less than one year
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6771000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11661000
CY2022Q1	beam	Accrued Research Costs AccruedResearchCosts	6545000
CY2021Q4	beam	Accrued Research Costs AccruedResearchCosts	3133000
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3542000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3330000
CY2022Q1	beam	Accrued Process Development And Manufacturing Costs AccruedProcessDevelopmentAndManufacturingCosts	2299000
CY2021Q4	beam	Accrued Process Development And Manufacturing Costs AccruedProcessDevelopmentAndManufacturingCosts	3833000
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4905000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6964000
CY2022Q1	beam	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	24062000
CY2021Q4	beam	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	28921000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4386000
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4558000
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	1136000
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	210000
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	232000
CY2022Q1	us-gaap	Sublease Income SubleaseIncome	331000
CY2021Q1	us-gaap	Sublease Income SubleaseIncome	0
CY2022Q1	us-gaap	Lease Cost LeaseCost	5423000
CY2021Q1	us-gaap	Lease Cost LeaseCost	4768000
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y7M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y1M6D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4509000
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	1685000
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4822000
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	23366000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	13865000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19006000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	19586000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	20066000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	17143000
CY2022Q1	beam	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	115692000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	205358000
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	59965000
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	145393000
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.64
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	20637
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	36.41
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18035000
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4648000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7264403
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.28
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2602709
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.40
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1427500
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	69.13
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	176652
CY2022Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of the Company’s common stock are entitled to one vote for each share of common stock.
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6034192
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.83
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	46.09
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8806929
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7496240
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-69214000
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-201560000
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68703864
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	68703864
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60210120
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60210120
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.35
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.35
CY2022Q1	beam	Number Of Founder Shareholders NumberOfFounderShareholders	3

Files In Submission

Name	View Source	Status
0000950170-22-008238-index-headers.html	Edgar Link	pending
0000950170-22-008238-index.html	Edgar Link	pending
0000950170-22-008238.txt	Edgar Link	pending
0000950170-22-008238-xbrl.zip	Edgar Link	pending
beam-20220331.htm	Edgar Link	pending
beam-20220331.xsd	Edgar Link	pending
beam-20220331_cal.xml	Edgar Link	unprocessable
beam-20220331_def.xml	Edgar Link	unprocessable
beam-20220331_htm.xml	Edgar Link	completed
beam-20220331_lab.xml	Edgar Link	unprocessable
beam-20220331_pre.xml	Edgar Link	unprocessable
beam-ex10_1.htm	Edgar Link	pending
beam-ex31_1.htm	Edgar Link	pending
beam-ex31_2.htm	Edgar Link	pending
beam-ex32_1.htm	Edgar Link	pending
beam-ex32_2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BEAM
Beam Therapeutics Inc. Stock $beam

2022 Q1 Form 10-Q Financial Statement

#000095017022008238 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BEAM Beam Therapeutics Inc. Stock $beam

2022 Q1 Form 10-Q Financial Statement

#000095017022008238 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BEAM
Beam Therapeutics Inc. Stock $beam